Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
Be 'active' in the market while NOT being tied to your desk.
...
Health Technology » Biotechnology
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| MRNA | Moderna, Inc. | -2.45% | 98.56 | 0.0% | $1438.14m | |
| BIIB | Biogen, Inc. | -0.36% | 242.51 | 1.7% | $630.38m | |
| AMGN | Amgen, Inc. | -0.79% | 220.46 | 1.3% | $568.17m | |
| GILD | Gilead Sciences, Inc. | 0.60% | 60.25 | 1.0% | $535.76m | |
| VRTX | Vertex Pharmaceuticals, Inc. | -0.63% | 216.50 | 1.9% | $470.81m | |
| REGN | Regeneron Pharmaceuticals, Inc. | -3.34% | 506.10 | 2.7% | $447.76m | |
| BNTX | BioNTech SE | -4.35% | 101.87 | 0.0% | $424.45m | |
| ILMN | Illumina, Inc. | 1.25% | 305.63 | 3.5% | $377.98m | |
| NVAX | Novavax, Inc. | 1.44% | 95.33 | 92.9% | $339.05m | |
| EXAS | EXACT Sciences Corp. | -2.72% | 117.26 | 19.6% | $289.27m | |
| MGEN | Miragen Therapeutics, Inc. | -4.62% | 16.50 | 0.7% | $248.55m | |
| SRRK | Scholar Rock Holding Corp. | 3.14% | 42.70 | 0.0% | $242.63m | |
| APVO | Aptevo Therapeutics, Inc. | -3.58% | 43.92 | 18.3% | $210.20m | |
| SGEN | Seagen Inc. | -2.05% | 164.63 | 5.8% | $167.34m | |
| ALXN | Alexion Pharmaceuticals, Inc. | 0.41% | 123.11 | 2.0% | $161.56m |
Company Profile
BioNTech SE operates as a clinical-stage biotechnology company. It operates through the following business units: Biotech Business and External Services. The Biotech Business unit consists of Clinical, Technology Platform and Manufacturing segments. It also includes business services operations. The External Services unit consists of External Services segment, which includes activities related to the sale of diagnostic products, peptides, retroviral vectors for clinical supply, development and manufacturing services. The company was founded by Christopher Huber, Ozlem Tureci and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.